Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wah Loong Chan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Alimentary Pharmacology & Therapeutics|October 23, 2024
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver DiseaseWah Loong Chan, Kee Huat Chuah
Hepatobiliary Surgery and Nutrition|October 27, 2023
Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitisWah Loong Chan, C Vikneshwaran Chandra Kumar, Wah Kheong Chan
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|April 15, 2026
Frequency, Predictive Factors, and Burden of Gastrointestinal Symptoms in Patients With Type 2 DiabetesWah-Loong Chan, Sarmila Sathiya Seelan, Jeyakantha Ratnasingam, et al.
Journal of Gastroenterology and Hepatology|July 1, 2024
LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver diseaseYong Wen Leow, Wah Loong Chan, Lee Lee Lai, et al.
Hepatology International|May 26, 2023
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsyWah-Loong Chan, Shi-En Chong, Felicia Chang, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2026
Letter: Rifaximin Versus Low FODMAP Diet in IBS: What the Primary Endpoint Does Not Tell Us. Authors' ReplyKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2025
Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. Authors' ReplyKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Alimentary Pharmacology & Therapeutics|October 16, 2025
Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel SyndromeKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Journal of Neurogastroenterology and Motility|November 20, 2025
Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in AsiaYi Ping Ren, Wah Loong Chan, Kee Huat Chuah, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Alimentary Pharmacology & Therapeutics|October 23, 2024
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver DiseaseWah Loong Chan, Kee Huat Chuah
Hepatobiliary Surgery and Nutrition|October 27, 2023
Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitisWah Loong Chan, C Vikneshwaran Chandra Kumar, Wah Kheong Chan
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|April 15, 2026
Frequency, Predictive Factors, and Burden of Gastrointestinal Symptoms in Patients With Type 2 DiabetesWah-Loong Chan, Sarmila Sathiya Seelan, Jeyakantha Ratnasingam, et al.
Journal of Gastroenterology and Hepatology|July 1, 2024
LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver diseaseYong Wen Leow, Wah Loong Chan, Lee Lee Lai, et al.
Hepatology International|May 26, 2023
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsyWah-Loong Chan, Shi-En Chong, Felicia Chang, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2026
Letter: Rifaximin Versus Low FODMAP Diet in IBS: What the Primary Endpoint Does Not Tell Us. Authors' ReplyKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Alimentary Pharmacology & Therapeutics|November 25, 2025
Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. Authors' ReplyKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Alimentary Pharmacology & Therapeutics|October 16, 2025
Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel SyndromeKee Huat Chuah, Qing Yuan Loo, Audrey Joe Chii Loh, et al.
Journal of Neurogastroenterology and Motility|November 20, 2025
Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in AsiaYi Ping Ren, Wah Loong Chan, Kee Huat Chuah, et al.
Pageof 1